Featured Research

from universities, journals, and other organizations

Promising new drug target for kidney disease

Date:
March 12, 2012
Source:
The Mount Sinai Hospital / Mount Sinai School of Medicine
Summary:
Researchers have identified a regulator protein that plays a crucial role in kidney fibrosis, a condition that leads to kidney failure. Finding this regulator provides a new therapeutic target for the millions of Americans affected by kidney failure.

Researchers from Mount Sinai School of Medicine have identified a regulator protein that plays a crucial role in kidney fibrosis, a condition that leads to kidney failure. Finding this regulator provides a new therapeutic target for the millions of Americans affected by kidney failure. The research is published in the March 11 issue of Nature Medicine.

Related Articles


Led by John Cijiang He, MD, PhD, Professor of Nephrology and Pharmacology and Systems Therapeutics; and Avi Ma'ayan, PhD, Assistant Professor of Pharmacology and Systems Therapeutics at Mount Sinai School of Medicine, the research team studied three mouse models of kidney fibrosis: one group of mice contained HIV viral proteins incorporated into their genome; the second group was injected with a high dose of folic acid; in the third mouse model, kidney filtration was blocked in one kidney. All of these factors cause kidney fibrosis.

The researchers gathered the genetic material of the mice and compared it to the genetic material of mice that did not have kidney fibrosis. Using a new computational systems biology algorithm and software called Expression2Kinases -- developed by the Ma'ayan Laboratory at Mount Sinai -- the results from these experiments were analyzed. They found that HIPK2, a protein kinase, or regulator, was highly active in the mice with kidney fibrosis. HIPK2 regulates the way certain genes are expressed and when HIPK2 is highly active this leads to kidney fibrosis. Drs. He and Ma'ayan also found that when they eliminated HIPK2, fibrosis was less prominent and the condition of the mice significantly improved.

"Our findings have important implications for people with kidney diseases, patients I treat every day," said Dr. He. "Protein kinases like HIPK2 are highly effective therapeutic targets. We look forward to exploring this further."

Incorporating a systems approach allowed the Mount Sinai team to identify a target that is a regulatory protein modified during chronic disease. The high activity of HIPK2 in kidney fibrosis was not identifiable by standard methods that examine gene expression changes alone, but by modeling a network of proteins using computational systems biology, the research team was able to home in on the regulator protein, HIPK2. Now, Mount Sinai scientists can work to develop a drug intervention that inhibits the activity of HIPK2.

"This study is an important example of the translational research we are doing at Mount Sinai," said Dr. Ma'ayan. "Using algorithms and software developed here, we worked with Dr. He, who is a kidney disease physician and scientist, to better understand what causes kidney fibrosis, and we are now one step closer to finding a therapeutic solution to a complex disease that affects millions of Americans."

Funding for this study was provided by the National Institute of Diabetes and Digestive and Kidney Diseases, a division of the National Institutes of Health in Bethesda, Md.


Story Source:

The above story is based on materials provided by The Mount Sinai Hospital / Mount Sinai School of Medicine. Note: Materials may be edited for content and length.


Journal Reference:

  1. Yuanmeng Jin, Krishna Ratnam, Peter Y Chuang, Ying Fan, Yifei Zhong, Yan Dai, Amin R Mazloom, Edward Y Chen, Vivette D'Agati, Huabao Xiong, Michael J Ross, Nan Chen, Avi Ma'ayan, John Cijiang He. A systems approach identifies HIPK2 as a key regulator of kidney fibrosis. Nature Medicine, 2012; DOI: 10.1038/nm.2685

Cite This Page:

The Mount Sinai Hospital / Mount Sinai School of Medicine. "Promising new drug target for kidney disease." ScienceDaily. ScienceDaily, 12 March 2012. <www.sciencedaily.com/releases/2012/03/120312003228.htm>.
The Mount Sinai Hospital / Mount Sinai School of Medicine. (2012, March 12). Promising new drug target for kidney disease. ScienceDaily. Retrieved March 31, 2015 from www.sciencedaily.com/releases/2012/03/120312003228.htm
The Mount Sinai Hospital / Mount Sinai School of Medicine. "Promising new drug target for kidney disease." ScienceDaily. www.sciencedaily.com/releases/2012/03/120312003228.htm (accessed March 31, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Tuesday, March 31, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

7-Year-Old Girl Gets 3-D Printed 'robohand'

7-Year-Old Girl Gets 3-D Printed 'robohand'

AP (Mar. 31, 2015) — Although she never had much interest in prosthetic limbs before, Faith Lennox couldn&apos;t wait to slip on her new robohand. The 7-year-old, who lost part of her left arm when she was a baby, grabbed it as soon as it came off a 3-D printer. (March 31) Video provided by AP
Powered by NewsLook.com
Solitair Device Aims to Takes Guesswork out of Sun Safety

Solitair Device Aims to Takes Guesswork out of Sun Safety

Reuters - Innovations Video Online (Mar. 31, 2015) — The Solitair device aims to take the confusion out of how much sunlight we should expose our skin to. Small enough to be worn as a tie or hair clip, it monitors the user&apos;s sun exposure by taking into account their skin pigment, location and schedule. Matthew Stock reports. Video provided by Reuters
Powered by NewsLook.com
Soda, Salt and Sugar: The Next Generation of Taxes

Soda, Salt and Sugar: The Next Generation of Taxes

Washington Post (Mar. 30, 2015) — Denisa Livingston, a health advocate for the Dinι Community Advocacy Alliance, and the Post&apos;s Abby Phillip discuss efforts around the country to make unhealthy food choices hurt your wallet as much as your waistline. Video provided by Washington Post
Powered by NewsLook.com
UnitedHealth Buys Catamaran

UnitedHealth Buys Catamaran

Reuters - Business Video Online (Mar. 30, 2015) — The $12.8 billion merger will combine the U.S.&apos; third and fourth largest pharmacy benefit managers. Analysts say smaller PBMs could also merge. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins